In a cohort of TRANSCEND FL, the chimeric antigen receptor T-cell therapy liso-cel showed a 95% overall response rate in relapsed marginal zone lymphoma, offering hope for improved patient outcomes in ...

The Food and Drug Administration (FDA) has approved Monjuvi ® (tafasitamab-cxix), in combination with lenalidomide and rituximab, for the treatment of adult patients with relapsed or refractory (R/R) ...

The U.S. Food and Drug Administration has approved Monjuvi (tafasitamab-cxix) for the treatment of adult patients with ...

Adding tafasitamab to treatment with lenalidomide and rituximab improved outcomes in patients with relapsed or refractory follicular lymphoma.

The most common effusions are malignant pleural effusions (MPEs) caused by lung cancer, breast cancer, lymphoma and so on, and benign pleural effusions (BPEs) caused by Mycobacterium tuberculosis ...